200 related articles for article (PubMed ID: 30999958)
1. Treatment of malignant pleural effusions: the case for localized immunotherapy.
Donnenberg AD; Luketich JD; Dhupar R; Donnenberg VS
J Immunother Cancer; 2019 Apr; 7(1):110. PubMed ID: 30999958
[TBL] [Abstract][Full Text] [Related]
2. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.
Donnenberg VS; Luketich JD; Sultan I; Lister J; Bartlett DL; Ghosh S; Donnenberg AD
Front Immunol; 2023; 14():1157697. PubMed ID: 37063842
[TBL] [Abstract][Full Text] [Related]
3. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
[TBL] [Abstract][Full Text] [Related]
4. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.
Liu Y; Wang L; Song Q; Ali M; Crowe WN; Kucera GL; Hawkins GA; Soker S; Thomas KW; Miller LD; Lu Y; Bellinger CR; Zhang W; Habib AA; Petty WJ; Zhao D
Nat Nanotechnol; 2022 Feb; 17(2):206-216. PubMed ID: 34916656
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
6. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion.
Wang D; Yang L; Yue D; Cao L; Li L; Wang D; Ping Y; Shen Z; Zheng Y; Wang L; Zhang Y
Cancer Lett; 2019 Jun; 452():244-253. PubMed ID: 30928379
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
[TBL] [Abstract][Full Text] [Related]
9. Current status of immunotherapy for gastrointestinal stromal tumor.
Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review).
He D; Ding R; Wen Q; Chen L
Int J Oncol; 2021 Mar; 58(3):359-370. PubMed ID: 33650668
[TBL] [Abstract][Full Text] [Related]
11. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.
Hori T; Mise K; Kan N; Okino T; Satoh K; Yamasaki S; Teramura Y; Harada T; Ohgaki K; Kodama H
Biotherapy; 1992; 5(1):21-9. PubMed ID: 1389900
[TBL] [Abstract][Full Text] [Related]
13. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.
Yang L; Wang F; Wang L; Huang L; Wang J; Zhang B; Zhang Y
Oncotarget; 2015 Apr; 6(12):10592-603. PubMed ID: 25871392
[TBL] [Abstract][Full Text] [Related]
14. Molecular Testing on Pleural Fluid Samples.
Oh S; Ronaghi R; Cai G
Semin Respir Crit Care Med; 2019 Jun; 40(3):340-346. PubMed ID: 31525809
[TBL] [Abstract][Full Text] [Related]
15. Expression of TCR zeta chain of tumor associated lymphocytes from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Adv Exp Med Biol; 2001; 495():325-9. PubMed ID: 11774587
[No Abstract] [Full Text] [Related]
16. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
17. A large quantity of CD3-/CD19-/CD16- lymphocytes in malignant pleural effusion from a patient with recurrent cholangio cell carcinoma.
Onishi H; Morisaki T; Kuga H; Katano M; Doi F; Uchiyama A; Sugitani A; Wada J; Chijiiwa K; Tanaka M
Immunol Invest; 2002 May; 31(2):121-35. PubMed ID: 12148948
[TBL] [Abstract][Full Text] [Related]
18. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
[TBL] [Abstract][Full Text] [Related]
19. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
